Cargando…
Plasmavigilance—Adverse events among US Source plasma donors
BACKGROUND: Source plasma (SP) is the primary starting material for 87% of plasma‐derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry. Donor retention depends on donors having a safe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291118/ https://www.ncbi.nlm.nih.gov/pubmed/34390267 http://dx.doi.org/10.1111/trf.16612 |
_version_ | 1784749069272350720 |
---|---|
author | Schreiber, George B. Becker, Mark Fransen, Michelle Hershman, Janet Lenart, James Song, Guang Simon, Toby |
author_facet | Schreiber, George B. Becker, Mark Fransen, Michelle Hershman, Janet Lenart, James Song, Guang Simon, Toby |
author_sort | Schreiber, George B. |
collection | PubMed |
description | BACKGROUND: Source plasma (SP) is the primary starting material for 87% of plasma‐derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry. Donor retention depends on donors having a safe and satisfactory experience. This study analyzes AE rates and SP donor characteristics that may be predictors of an AE. STUDY DESIGN AND METHODS: Donation data for 1.1 million donors making 12,183,182 SP donations over a 4‐month period were analyzed. This represented approximately 72% of the donations collected by the U.S. plasma industry. The Standard for Recording Donor Adverse Events was used for AE definitions and classifications. RESULTS: The overall AE rate was 15.85/10(4) donations. The two AEs with the highest rates were Hypotensive and Phlebotomy events (8.32 and 5.91/10(4) donations, respectively). Females had higher overall AE rates than males (25.76 vs. 9.85/10(4) donations), and first‐time donors had higher overall AE rates than repeat donors (136.66 vs. 12.37/10(4) donations). Weight, body mass index, age, and pre‐donation estimated blood volume also were predictors of AE. DISCUSSION: SP donors have low AE rates with 90% being events classified as Hypotensive or Phlebotomy. Special attention and mitigation strategies should be directed to donors who are young, lightweight (between 100 and 124 pounds), female, or first‐time donors to further reduce the incidence of AE, continue to ensure the donor has a safe experience, and facilitate donor retention. |
format | Online Article Text |
id | pubmed-9291118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92911182022-07-20 Plasmavigilance—Adverse events among US Source plasma donors Schreiber, George B. Becker, Mark Fransen, Michelle Hershman, Janet Lenart, James Song, Guang Simon, Toby Transfusion Blood Donors and Blood Collection BACKGROUND: Source plasma (SP) is the primary starting material for 87% of plasma‐derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry. Donor retention depends on donors having a safe and satisfactory experience. This study analyzes AE rates and SP donor characteristics that may be predictors of an AE. STUDY DESIGN AND METHODS: Donation data for 1.1 million donors making 12,183,182 SP donations over a 4‐month period were analyzed. This represented approximately 72% of the donations collected by the U.S. plasma industry. The Standard for Recording Donor Adverse Events was used for AE definitions and classifications. RESULTS: The overall AE rate was 15.85/10(4) donations. The two AEs with the highest rates were Hypotensive and Phlebotomy events (8.32 and 5.91/10(4) donations, respectively). Females had higher overall AE rates than males (25.76 vs. 9.85/10(4) donations), and first‐time donors had higher overall AE rates than repeat donors (136.66 vs. 12.37/10(4) donations). Weight, body mass index, age, and pre‐donation estimated blood volume also were predictors of AE. DISCUSSION: SP donors have low AE rates with 90% being events classified as Hypotensive or Phlebotomy. Special attention and mitigation strategies should be directed to donors who are young, lightweight (between 100 and 124 pounds), female, or first‐time donors to further reduce the incidence of AE, continue to ensure the donor has a safe experience, and facilitate donor retention. John Wiley & Sons, Inc. 2021-08-14 2021-10 /pmc/articles/PMC9291118/ /pubmed/34390267 http://dx.doi.org/10.1111/trf.16612 Text en © 2021 Plasma Protein Therapeutics Association. Transfusion published by Wiley Periodicals LLC on behalf of AABB. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Blood Donors and Blood Collection Schreiber, George B. Becker, Mark Fransen, Michelle Hershman, Janet Lenart, James Song, Guang Simon, Toby Plasmavigilance—Adverse events among US Source plasma donors |
title | Plasmavigilance—Adverse events among US Source plasma donors |
title_full | Plasmavigilance—Adverse events among US Source plasma donors |
title_fullStr | Plasmavigilance—Adverse events among US Source plasma donors |
title_full_unstemmed | Plasmavigilance—Adverse events among US Source plasma donors |
title_short | Plasmavigilance—Adverse events among US Source plasma donors |
title_sort | plasmavigilance—adverse events among us source plasma donors |
topic | Blood Donors and Blood Collection |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291118/ https://www.ncbi.nlm.nih.gov/pubmed/34390267 http://dx.doi.org/10.1111/trf.16612 |
work_keys_str_mv | AT schreibergeorgeb plasmavigilanceadverseeventsamongussourceplasmadonors AT beckermark plasmavigilanceadverseeventsamongussourceplasmadonors AT fransenmichelle plasmavigilanceadverseeventsamongussourceplasmadonors AT hershmanjanet plasmavigilanceadverseeventsamongussourceplasmadonors AT lenartjames plasmavigilanceadverseeventsamongussourceplasmadonors AT songguang plasmavigilanceadverseeventsamongussourceplasmadonors AT simontoby plasmavigilanceadverseeventsamongussourceplasmadonors |